Asensus Surgical Shares Rise 8% on FDA Approval of New Instruments

By Chris Wack

Asensus Surgical Inc. shares were up 8% to $2.33 in early trade Wednesday after the company said it has received Food & Drug Administration 510(k) clearance for 5 mm diameter articulating instruments, adding to the Senhance Surgical System technology platform.

The medical device company said the articulating instruments offer better access to difficult-to-reach areas of the anatomy by providing two additional degrees of freedom. These instruments have previously received CE Mark for use in the European Union.

Asensus Surgical's technology platform, the Senhance Surgical System, is a digital laparoscopic platform that uses augmented intelligence to provide unmatched performance and patient outcomes through machine learning.

Write to Chris Wack at [e-mail]

(END) Dow Jones Newswires

07-28-21 0954ET